Please Wait
Applying Filters...
Menu
Xls
2D Structure
Also known as: Patidegib, Ipi-926, 1037210-93-7, Ipi 926, Ip9 free base, Fin-5
Molecular Formula
C29H48N2O3S
Molecular Weight
504.8  g/mol
InChI Key
HZLFFNCLTRVYJG-WWGOJCOQSA-N
FDA UNII
JT96FPU35X

Patidegib is an orally bioavailable, cyclopamine-derived inhibitor of the Hedgehog (Hh) pathway with potential antineoplastic activity. Specifically, patidegib binds to and inhibits the cell membrane-spanning G-protein coupled receptor SMO, which may result in the suppression of Hh pathway signaling and a decrease in tumor cell proliferation and survival. SMO is activated upon binding of Hh ligand to the cell surface receptor Patched (PTCH); inappropriate activation of Hh signaling and uncontrolled cellular proliferation may be associated with SMO mutations. The Hh signaling pathway plays an important role in proliferation of neuronal precursor cells in the developing cerebellum and other tissues.
1 2D Structure

2D Structure

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-[(3R,3'R,3'aS,4aR,6'S,6aR,6bS,7'aR,9S,12aS,12bS)-3',6',11,12b-tetramethylspiro[1,2,3,4,4a,5,6,6a,6b,7,8,10,12,12a-tetradecahydronaphtho[2,1-a]azulene-9,2'-3a,4,5,6,7,7a-hexahydro-3H-furo[3,2-b]pyridine]-3-yl]methanesulfonamide
2.1.2 InChI
InChI=1S/C29H48N2O3S/c1-17-12-26-27(30-16-17)19(3)29(34-26)11-9-22-23-7-6-20-13-21(31-35(5,32)33)8-10-28(20,4)25(23)14-24(22)18(2)15-29/h17,19-23,25-27,30-31H,6-16H2,1-5H3/t17-,19+,20+,21+,22-,23-,25-,26+,27-,28-,29-/m0/s1
2.1.3 InChI Key
HZLFFNCLTRVYJG-WWGOJCOQSA-N
2.1.4 Canonical SMILES
CC1CC2C(C(C3(O2)CCC4C5CCC6CC(CCC6(C5CC4=C(C3)C)C)NS(=O)(=O)C)C)NC1
2.1.5 Isomeric SMILES
C[C@H]1C[C@@H]2[C@H]([C@H]([C@]3(O2)CC[C@H]4[C@@H]5CC[C@@H]6C[C@@H](CC[C@@]6([C@H]5CC4=C(C3)C)C)NS(=O)(=O)C)C)NC1
2.2 Other Identifiers
2.2.1 UNII
JT96FPU35X
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Ipi-926

2.3.2 Depositor-Supplied Synonyms

1. Patidegib

2. Ipi-926

3. 1037210-93-7

4. Ipi 926

5. Ip9 Free Base

6. Fin-5

7. Jt96fpu35x

8. Ipi-926 Free Base

9. Chembl538867

10. Ip-9

11. Patidegib (usan)

12. Patidegib [usan]

13. N-[(3r,3'r,3'as,4ar,6's,6ar,6bs,7'ar,9s,12as,12bs)-3',6',11,12b-tetramethylspiro[1,2,3,4,4a,5,6,6a,6b,7,8,10,12,12a-tetradecahydronaphtho[2,1-a]azulene-9,2'-3a,4,5,6,7,7a-hexahydro-3h-furo[3,2-b]pyridine]-3-yl]methanesulfonamide

14. N-((2s,3r,3as,3'r,4a'r,6s,6a'r,6b's,7ar,12a's,12b's)-3,6,11',12b'-tetramethyl-2',3a,3',4,4',4a',5,5',6,6',6a',6b',7,7a,7',8',10',12',12a',12b'-icosahydro-1'h,3h-spiro[furo[3,2-b]pyridine-2,9'-naphtho[2,1-a]azulen]-3'-yl)methanesulfonamide

15. Patidegib [usan:inn]

16. Unii-jt96fpu35x

17. Saridegib [rescinded Usan]

18. Patidegib [inn]

19. Patidegib [who-dd]

20. Schembl421999

21. Gtpl8198

22. Dtxsid40146032

23. Chebi:177425

24. Saridegib (ipi-926; Patidegib)

25. Who 9619

26. Bdbm50293788

27. Zinc43197072

28. Db12655

29. Hy-16587

30. Cs-0007501

31. D10324

32. Q15426668

33. Methanesulfonamide, N-((2s,3r,3'r,3as,4'ar,6s,6'ar,6'bs,7ar,12'as,12'bs)- 2',3',3a,4,4',4'a,5,5',6,6',6'a,6'b,7,7',7a,8',10',12',12'a,12'b-eicosahydro-3,6,11',12'b-tetramethylspiro(furo(3,2-b)pyridine-2(3h),9'(1'h)-naphth(2,1-a)azulen)-3'-yl)-

34. Methanesulfonamide, N-((2s,3r,3'r,3as,4'ar,6s,6'ar,6'bs,7ar,12'as,12'bs)-2',3',3a,4,4',4'a,5,5',6,6',6'a,6'b,7,7',7a,8',10',12',12'a,12'b-eicosahydro-3,6,11',12'b-tetramethylspiro(furo(3,2-b)pyridine-2(3h),9'(1'h)-naphth(2,1-a)azulen)-3'-yl)-

35. N-((2s,3r,3as,3''r,4a''r,6s,6a''r,6b''s,7ar,12a''s,12b''s)-3,6,11'',12b''-tetramethyl-2'',3a,3'',4,4'',4a'',5,5'',6,6'',6a'',6b'',7,7a,7'',8'',10'',12'',12a'',12b''-icosahydro-1''h,3h-spiro[furo[3,2-b]pyridine-2,9''-naphtho[2,1-a]azulene]-3''-yl)methanesulfonamide

36. N-[(3r,3'r,3'as,4ar,6's,6ar,6bs,7'ar,9s,12as,12bs)-3',6',11,12b-tetramethylspiro[1,2,3,4,4a,5,6,6a,6b,7,8,10,12,12a-tetradecahydronaphtho[2,1-a]azulene-9,2'-3a,4,5,6,7,7a-hexahydro-3h-uro[3,2-b]pyridine]-3-yl]methanesulonamide

2.4 Create Date
2008-11-17
3 Chemical and Physical Properties
Molecular Weight 504.8 g/mol
Molecular Formula C29H48N2O3S
XLogP34.6
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count5
Rotatable Bond Count2
Exact Mass504.33856457 g/mol
Monoisotopic Mass504.33856457 g/mol
Topological Polar Surface Area75.8 Ų
Heavy Atom Count35
Formal Charge0
Complexity988
Isotope Atom Count0
Defined Atom Stereocenter Count11
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Treatment of naevoid basal-cell carcinoma syndrome (Gorlin syndrome)